Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity

Journal of Immunology

Volumn 185, Issue 9, 2010, Pages 5512-5521

  Lissilaa, Rami ^a,d   Buatois, Vanessa ^a   Magistrelli, Giovanni ^a   Williams, Anwen S ^b   Jones, Gareth W ^b,c   Herren, Suzanne ^a   Shang, Limin ^a   Malinge, Pauline ^a   Guilhot, Florence ^a   Chatel, Laurence ^a   Hatterer, Eric ^a   Jones, Simon A ^b   Kosco Vilbois, Marie H ^a   Ferlin, Walter G ^a  

^a NOVIMMUNE SA   (Switzerland)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d Glenmark Pharmaceuticals   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; CYTOKINE; INTERLEUKIN 6 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTHRITIS; ARTHROPATHY; ARTICLE; AUTOIMMUNITY; CELL TYPE; EVOKED RESPONSE; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOID ORGAN; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL SEPARATION; DBA MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNITY; CELL SEPARATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; RECEPTORS, INTERLEUKIN-6; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; T-LYMPHOCYTES; TRANSFECTION;

EID: 78149474747     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002015     Document Type: Article

References (58)

1. O'Shea, J. J., A. Ma, and P. Lipsky. 2002. Cytokines and autoimmunity. Nat. Rev. Immunol. 2:37-45.
2. McInnes, I. B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7:429-442.
3. Fattori, E., M. Cappelletti, P. Costa, C. Sellitto, L. Cantoni, M. Carelli, R. Faggioni, G. Fantuzzi, P. Ghezzi, and V. Poli. 1994. Defective inflammatory response in interleukin 6-deficient mice. J. Exp. Med. 180:1243-1250.
4. Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bluethmann, and G. Köhler. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339-342.
5. Kopf, M., S. Herren, M. V. Wiles, M. B. Pepys, and M. H. Kosco-Vilbois. 1998. Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J. Exp. Med. 188:1895-1906.
6. Desgeorges, A., C. Gabay, P. Silacci, D. Novick, P. Roux-Lombard, G. Grau, J. M. Dayer, T. Vischer, and P. A. Guerne. 1997. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J. Rheumatol. 24:1510-1516.
7. Mudter, J., and M. F. Neurath. 2007. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm. Bowel Dis. 13:1016-1023.
8. Saito, M., K. Yoshida, M. Hibi, T. Taga, and T. Kishimoto. 1992. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J. Immunol. 148:4066-4071.
9. Hirata, Y., T. Taga, M. Hibi, N. Nakano, T. Hirano, and T. Kishimoto. 1989. Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies. J. Immunol. 143:2900-2906.
10. Rose-John, S., and P. C. Heinrich. 1994. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 300:281-290.
11. Hurst, S. M., T. S. Wilkinson, R. M. McLoughlin, S. Jones, S. Horiuchi, N. Yamamoto, S. Rose-John, G. M. Fuller, N. Topley, and S. A. Jones. 2001. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14:705-714.
12. Nowell, M. A., P. J. Richards, S. Horiuchi, N. Yamamoto, S. Rose-John, N. Topley, A. S. Williams, and S. A. Jones. 2003. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. 171:3202-3209.
13. McLoughlin, R. M., B. J. Jenkins, D. Grail, A. S. Williams, C. A. Fielding, C. R. Parker, M. Ernst, N. Topley, and S. A. Jones. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc. Natl. Acad. Sci. USA 102:9589-9594.
14. Buell, G., I. P. Chessell, A. D. Michel, G. Collo, M. Salazzo, S. Herren, D. Gretener, C. Grahames, R. Kaur, M. H. Kosco-Vilbois, and P. P. Humphrey. 1998. Blockade of human P2X7 receptor function with a monoclonal antibody. Blood 92:3521-3528.
15. Brackertz, D., G. F. Mitchell, and I. R. Mackay. 1977. Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum. 20:841-850.
16. Stumhofer, J. S., A. Laurence, E. H. Wilson, E. Huang, C. M. Tato, L. M. Johnson, A. V. Villarino, Q. Huang, A. Yoshimura, D. Sehy, et al. 2006. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7:937-945.
17. Yang, X. O., A. D. Panopoulos, R. Nurieva, S. H. Chang, D. Wang, S. S. Watowich, and C. Dong. 2007. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282:9358-9363.
18. Boe, A., M. Baiocchi, M. Carbonatto, R. Papoian, and O. Serlupi-Crescenzi. 1999. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 11:1057-1064.
19. Ohshima, S., Y. Saeki, T. Mima, M. Sasai, K. Nishioka, S. Nomura, M. Kopf, Y. Katada, T. Tanaka, M. Suemura, and T. Kishimoto. 1998. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl. Acad. Sci. USA 95:8222-8226.
20. Wong, P. K., P. J. Egan, B. A. Croker, K. O'Donnell, N. A. Sims, S. Drake, H. Kiu, E. J. McManus, W. S. Alexander, A. W. Roberts, and I. P. Wicks. 2006. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J. Clin. Invest. 116:1571-1581.
21. Nowell, M. A., A. S. Williams, S. A. Carty, J. Scheller, A. J. Hayes, G. W. Jones, P. J. Richards, S. Slinn, M. Ernst, B. J. Jenkins, et al. 2009. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J. Immunol. 182:613-622.
22. Richards, P. J., M. A. Nowell, S. Horiuchi, R. M. McLoughlin, C. A. Fielding, S. Grau, N. Yamamoto, M. Ehrmann, S. Rose-John, A. S. Williams, et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model ofinflammatory arthritis. Arthritis Rheum. 54:1662-1672.
23. Brand, D. D., A. H. Kang, and E. F. Rosloniec. 2003. Immunopathogenesis of collagen arthritis. Springer Semin. Immunopathol. 25:3-18.
24. Nandakumar, K. S., J. Bäcklund, M. Vestberg, and R. Holmdahl. 2004. Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells. Arthritis Res. Ther. 6: R544-R550.
25. Furuzawa-Carballeda, J., M. I. Vargas-Rojas, and A. R. Cabral. 2007. Autoimmune inflammation from the Th17 perspective. Autoimmun. Rev. 6:169-175.
26. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171:6173-6177.
27. Becker, C., M. C. Fantini, C. Schramm, H. A. Lehr, S. Wirtz, A. Nikolaev, J. Burg, S. Strand, R. Kiesslich, S. Huber, et al. 2004. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21:491-501.
28. Atreya, R., J. Mudter, S. Finotto, J. Müllberg, T. Jostock, S. Wirtz, M. Schütz, B. Bartsch, M. Holtmann, C. Becker, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6:583-588.
29. Teague, T. K., P. Marrack, J. W. Kappler, and A. T. Vella. 1997. IL-6 rescues resting mouse T cells from apoptosis. J. Immunol. 158:5791-5796.
30. Kishimoto, T. 1989. The biology of interleukin-6. Blood 74:1-10.
31. Taga, T., Y. Kawanishi, R. R. Hardy, T. Hirano, and T. Kishimoto. 1987. Receptors for B cell stimulatory factor 2: quantitation, specificity, distribution, and regulation of their expression. J. Exp. Med. 166:967-981.
32. Wu, Y., S. Sukumar, M. E. El Shikh, A. M. Best, A. K. Szakal, and J. G. Tew. 2008. Immune complex-bearing follicular dendritic cells deliver a late antigenic signal that promotes somatic hypermutation. J. Immunol. 180:281-290.
33. Hirano, T. 1991. Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias. Int. J. Cell Cloning 9:166-184.
34. Alonzi, T., E. Fattori, D. Lazzaro, P. Costa, L. Probert, G. Kollias, F. De Benedetti, V. Poli, and G. Ciliberto. 1998. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187:461-468.
35. Bongioanni, P., S. Mosti, M. R. Romano, F. Lombardo, G. Moscato, and G. Meucci. 2000. Increased T-lymphocyte interleukin-6 binding in patients with multiple sclerosis. Eur. J. Neurol. 7:291-297.
36. Lock, C., G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren, A. Langer-Gould, S. Strober, B. Cannella, J. Allard, et al. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8:500-508.
37. Linker, R. A., F. Lühder, K. J. Kallen, D. H. Lee, B. Engelhardt, S. Rose-John, and R. Gold. 2008. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. J. Neuroimmunol. 205:64-72.
38. Ogura, H., M. Murakami, Y. Okuyama, M. Tsuruoka, C. Kitabayashi, M. Kanamoto, M. Nishihara, Y. Iwakura, and T. Hirano. 2008. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29:628-636.
39. Fujimoto, M., S. Serada, M. Mihara, Y. Uchiyama, H. Yoshida, N. Koike, Y. Ohsugi, T. Nishikawa, B. Ripley, A. Kimura, et al. 2008. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 58:3710-3719.
40. Boulanger, M. J., D. C. Chow, E. E. Brevnova, and K. C. Garcia. 2003. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300:2101-2104.
41. Kotake, S., K. Sato, K. J. Kim, N. Takahashi, N. Udagawa, I. Nakamura, A. Yamaguchi, T. Kishimoto, T. Suda, and S. Kashiwazaki. 1996. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11:88-95.
42. Mihara, M., Y. Moriya, T. Kishimoto, and Y. Ohsugi. 1995. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br. J. Rheumatol. 34:321-325.
43. Franchimont, N., S. Rydziel, A. M. Delany, and E. Canalis. 1997. Interleukin-6 and its soluble receptor cause a marked induction of collagenase 3 expression in rat osteoblast cultures. J. Biol. Chem. 272:12144-12150.
44. Topley, N., T. Liberek, A. Davenport, F. K. Li, H. Fear, and J. D. Williams. 1996. Activation of inflammation and leukocyte recruitment into the peritoneal cavity. Kidney Int. Suppl. 56: S17-S21.
45. Jones, S. A., D. Novick, S. Horiuchi, N. Yamamoto, A. J. Szalai, and G. M. Fuller. 1999. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J. Exp. Med. 189:599-604.
46. Marin, V., F. A. Montero-Julian, S. Grès, V. Boulay, P. Bongrand, C. Farnarier, and G. Kaplanski. 2001. The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J. Immunol. 167:3435-3442.
47. Jones, S. A., and S. Rose-John. 2002. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim. Biophys. Acta 1592:251-263.
48. Romano, M., M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, et al. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:315-325.
49. Andersson, M., and R. Holmdahl. 1990. Analysis of type II collagen-reactive T cells in the mouse. I. Different regulation of autoreactive vs. non-autoreactive anti-type II collagen T cells in the DBA/1 mouse. Eur. J. Immunol. 20:1061-1066.
50. Kadowaki, K. M., H. Matsuno, H. Tsuji, and I. Tunru. 1994. CD4+ T cells from collagen-induced arthritic mice are essential to transfer arthritis into severe combined immunodeficient mice. Clin. Exp. Immunol. 97:212-218.
51. Silver, J. S., and C. A. Hunter. 2008. With a little help from their friends: interleukin-21, T cells, and B cells. Immunity 29:7-9.
52. Nurieva, R. I., Y. Chung, D. Hwang, X. O. Yang, H. S. Kang, L. Ma, Y. H. Wang, S. S. Watowich, A. M. Jetten, Q. Tian, and C. Dong. 2008. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29:138-149.
53. Zotos, D., J. M. Coquet, Y. Zhang, A. Light, K. D'Costa, A. Kallies, L. M. Corcoran, D. I. Godfrey, K. M. Toellner, M. J. Smyth, et al. 2010. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J. Exp. Med. 207:365-378.
54. Young, D. A., M. Hegen, H. L. Ma, M. J. Whitters, L. M. Albert, L. Lowe, M. Senices, P. W. Wu, B. Sibley, Y. Leathurby, et al. 2007. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 56:1152-1163.
55. Kawano, M. M., K. Mihara, N. Huang, T. Tsujimoto, and A. Kuramoto. 1995. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 85:487-494.
56. Roldán, E., and J. A. Brieva. 1991. Terminal differentiation of human bone marrow cells capable of spontaneous and high-rate immunoglobulin secretion: role of bone marrow stromal cells and interleukin 6. Eur. J. Immunol. 21:2671-2677.
57. Notley, C. A., J. J. Inglis, S. Alzabin, F. E. McCann, K. E. McNamee, and R. O. Williams. 2008. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J. Exp. Med. 205:2491-2497.
58. Nishimoto, N. 2010. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin. Pharmacol. Ther. 87:483-487.